Global Opioid Withdrawal Treatment Market

MARKET SCOPE:

The global opioid withdrawal treatment market is projected to grow significantly, registering a CAGR of 10.3% during the forecast period (2024 – 2032).

Pharmacological intervention becomes necessary when symptoms of opioid withdrawal are evident and require treatment. A In certain instances, the use of opioids can lead to addiction, and opioid withdrawal syndrome poses a life-threatening risk for those dependent on opioids. Additionally, these substances may contribute to serious health complications and, in some cases, lead to overdose and fatalities. As a result, the treatment of opioid dependence becomes imperative, commonly referred to as opioids withdrawal treatment. This abrupt ailment arises from the inappropriate use of opioid medications, incorrect treatments, and even substance dependency. Opioid medicines are typically prescribed for chronic and debilitating conditions, but their misuse elevates both morbidity and mortality rates. The primary goal of these medications is to diminish the likelihood of relapse. Patients with Opioid Use Disorder (OUD) seek abstinence, and the misuse or diversion of prescribed opioids contributes significantly to this challenge. Certain reports indicate a correlation between opioid addiction and life-threatening circumstances.

According to the Centers for Disease Control and Prevention (CDC) data, there were 33,000 fatalities in 2015 attributed to the misuse of this particular drug. The escalating rate of overdoses associated with this substance is on the rise. Reports indicate that this drug is among the most potent and efficacious for managing pain, with widespread applications in cancer pain treatment and various other medical contexts. The growing prevalence of its use is raising significant concerns on a global scale.

MARKET OVERVIEW:

Driver: Growing popularity of rehab centers as well as need for protecting youngsters from drug abuse are predicted to foster the market growth.

Tricksters have evolved their strategies to ensnare children, taking advantage of the vulnerability of the younger generation. Over time, these susceptible youngsters fall prey to various substances, developing drug addictions, leading to a substantial surge in drug usage. The global healthcare sector is grappling with the challenge of pharmaceuticals being misused for addressing sadness and anxiety. Recognizing the need to mitigate the adverse effects of prolonged drug use, opioid withdrawal treatment has emerged as a crucial domain in healthcare. Furthermore, healthcare professionals are increasingly vocal about the exploitation of youth by drug dealers, subtly contributing to the expansion of the market for opiate withdrawal treatments.

Growing concerns among parents about their children's mental well-being, coupled with heightened public awareness of the drug epidemic, have recently propelled the worldwide industry for opiate withdrawal treatment. Government officials have responded by implementing practical measures to prevent young adults from succumbing to drug misuse, including the establishment of treatment facilities catering to those experiencing symptoms of opioid withdrawal. The escalating number of individuals seeking rehabilitation to break free from drug dependency has significantly fueled the global expansion of the market for opioid withdrawal treatments. Additionally, the imperative to ensure a balanced life for diverse groups has generated a new demand for opiate withdrawal treatments.

Opportunities: The rise in disease of osteoarthritis is expected to pave the way for market growth in the upcoming years.

The market exhibits significant potential for further expansion in the coming years, primarily driven by the sustained growth of osteoarthritis in both the United Kingdom and the United States. This escalating prevalence serves as a pivotal factor contributing to the market's consistent upward trajectory. Moreover, findings from the International Journal of Immunopathology and Pharmacology underscore the widespread occurrence of neuropathic pain, estimating a prevalence rate ranging from 3% to 17% in 2019 among the population. This substantial prevalence of neuropathic pain further establishes itself as a key driver behind the market's growth. The combination of these factors presents promising opportunities for increased demand for the relevant medication, particularly in the healthcare landscapes of the United States and the United Kingdom. As the prevalence of conditions such as osteoarthritis and neuropathic pain continues to rise, the pharmaceutical market is well-positioned to capitalize on these emerging trends in the upcoming years.

COVID IMPACT:

The global impact of the deadly COVID-19 virus has significantly disrupted numerous businesses worldwide. The pandemic enforced isolation periods for affected individuals, instilling fear among physicians about recommending certain drugs, especially in the context of COVID-19-related pain. The prolonged pandemic also hampered the treatment of chronic pain patients, leading to the heightened use of a particular drug. This increased usage resulted in pronounced feelings of nausea and heightened anxiety among patients. Additionally, the ongoing challenges of osteoarthritis and the aging population emerged as key factors prompting the withdrawal of this medication.

The COVID-19 outbreak created a profound health crisis, causing substantial upheaval globally. Economic conditions suffered a severe blow, with the market experiencing a 10% increase during this period. The growth of the opioid withdrawal treatment market primarily targeted chronic pain patients and senior citizens, witnessing significant expansion in the United States and the European Union. The withdrawal of this medication was also in high demand in the painful diabetic neuropathy market. Despite the challenging circumstances, the opioid withdrawal treatment market saw substantial profits during the pandemic due to a reduction in pain among patients. In 2018, the United States Food and Drug Administration (FDA) introduced a policy aimed at curbing the misuse of opioids, which posed a high risk of additional diseases among patients. However, specific government initiatives in response to this policy are not explicitly mentioned.

SEGMENTATION ANALYSIS:

Based on drug type segment, Buprenorphine subsegment is anticipated to grow significantly during the forecast period.

The surge in growth can be attributed to the escalating usage of these medications in well-developed markets such as France and the United States. Additionally, the increased adoption of this drug can be ascribed to its notable efficacy in managing addiction, characterized by a low potential for abuse, relatively mild adverse effects, and favorable formulary coverage. Notably, Buprenorphine/naloxone sublingual tablets, buprenorphine sublingual tablets, and the branded Suboxone stand out as the most commonly prescribed drugs for treating Opioid Use Disorder. Furthermore, the suboxone film, with its outstanding clinical profile, emerges as the most prescribed medication in the Opioid Disorder treatment market, thereby contributing significantly to the growth of this segment.

Based on application segment, Hospital subsegment holds the highest market share for opioid withdrawal treatment.

Hospitals serve as the main healthcare facilities equipped with a substantial presence of highly trained and skilled staff and professionals, facilitating patients in obtaining effective treatment. Additionally, the endorsement and implementation of prescribed therapies within clinics and hospitals contribute to physician-supervised drug administration. This stands as a significant driver for the increased sales of opioids through hospital pharmacies. Furthermore, medications like 'naloxone,' an opioid-analgesic, are provided free of charge in hospital pharmacies, enhancing accessibility for patients dealing with Opioid Use Disorders. These combined factors are anticipated to propel the growth of this segment.

REGIONAL ANALYSIS:

The North America region is set to witness significant growth during the forecast period.

North America holds the highest share of market owing to well-established health infrastructure and prominent manufacturers. North America takes the lead in the opioid withdrawal treatment medication industry, owing to its substantial manufacturing facilities and a robust healthcare infrastructure. The region is poised to maintain global dominance in the opioid withdrawal treatment market, propelled by the heightened prevalence of chronic diseases and the escalating use of opioid medications for pain management. The anticipated largest market share globally is a reflection of North America's prominent position. Furthermore, the market is expected to witness significant growth, driven by the expanding array of product offerings from key industry players, resulting in a substantial Compound Annual Growth Rate (CAGR). Additionally, during the forecast period, North America is expected to secure the second-largest market share for diverticular disease treatments.

COMPETITIVE ANALYSIS

The global opioid withdrawal treatment market is reasonably competitive with mergers, acquisitions, and product launches. See some of the major key players in the market.

Alkermes

• In November 2023, Akili Interactive has revealed that its experimental digital therapeutic, AKL-T01 by Akili Interactive Labs, has received Breakthrough Therapy Designation from the FDA for addressing opioid withdrawal syndrome. AKL-T01, a non-invasive, prescription digital therapeutic, employs a video game-style interface to assist patients in effectively handling the symptoms associated with opioid withdrawal.

Merck & Co.

Teva Pharmaceutical Industries Ltd

Pfizer Inc.

Novartis

Sanofi

Johnson & Johnson Services

Hoffmann-La Roche Ltd

Bayer AG

SCOPE OF THE REPORT

By Type

• Anti-Inflammatory Drugs
• Anti-Nausea Medications
• Analgesics
• Others

By Drug Type

• Romiplostim
• Omidubicel
• Nalmefene
• Buprenorfine
• Methadone
• Naltrexone

By Application

• Hospital Pharmacy
• Retail Pharmacies
• Online Stores

By Region

• North America (the United States & Canada)
• Europe (Germany, UK, France, Spain, Italy, and the Rest of Europe)
• Asia Pacific (China, Japan, India, and Rest of Asia Pacific)
• Rest of the World (the Middle East & Africa, and Latin America)

KEY REASONS TO PURCHASE THIS REPORT

It provides a technological development map over time to understand the industry’s growth rate and indicates how the opioid withdrawal treatment market is evolving.

The report offers a dynamic method to various factors that drive or restrain the growth of the market and specifies which opioid withdrawal treatment submarket will be the main driver of the overall market from 2024 to 2032.

It renders a definite analysis of changing competitive dynamics and stipulates the leading players and what are their prospects over the forecast period.

It builds a nine-year estimate based on how the market is predicted to grow and shows what will market shares of the global region change by 2032 and which country will lead the market in 2032. Show more